RLFTF — MindMaze Therapeutics Holding SA

OTC · Health Care · Pharmaceuticals · CIK 1854078 · Switzerland
Last close
$0.38
Market Cap
$4.72M
52W High
$0.61
52W Low
$0.33
ADV30
3,877
Next earnings
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2025 47,987,000 12,500,000 15,354,000
Dec 2024 53,224,000 15,080,000 16,560,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-240,222,000
Inventory
$923,000
Receivables
$1,468,000
ST Investments
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$642,000
EBITDA
$-9,143,000
Free Cash Flow
Enterprise Value
Total Cash
Total Debt
Shares Out
12,591,919
Trailing EPS
$-1.70
Book Value
$3.26
ROE
-51.6%
ROA
-25.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 8,417,000 -7,906,000 -17,119,000 53,224,000 16,560,000 -2,916,000
Dec 2023 6,033,000 -19,778,000 -98,181,000 76,390,000 24,162,000 -17,612,000
Dec 2022 6,081,000 -35,474,000 -50,790,000 188,798,000 43,381,000 -24,126,000
Dec 2021 3,321,000 -34,611,000 -34,705,000 251,618,000 70,088,000 -35,718,000

Peers — same industry

TickerNameMarket CapLastDaily %
ARTL ARTELO BIOSCIENCES, INC. $4.74M $1.36
DRMA Dermata Therapeutics, Inc. $4.75M $1.18
AVCRF Avricore Health Inc. $4.63M $0.05
ALZN Alzamend Neuro, Inc. $4.60M $1.21
FBLG FibroBiologics, Inc. $4.85M $0.93

News headlines (Yahoo Finance, 1h cache)

MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting
2026-06-03 05:00 · Yahoo
MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification
2026-06-02 05:05 · Yahoo
MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
2026-05-26 05:50 · Yahoo
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
2026-05-12 05:25 · Yahoo
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
2026-03-19 06:35 · Yahoo
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
2026-03-12 07:44 · Yahoo
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
2026-03-03 07:45 · Yahoo
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
2025-12-23 06:20 · Yahoo
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
2025-12-15 06:20 · Yahoo
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
2025-11-14 17:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.